The renin-angiotensin-aldosterone system blockade and arterial stiffness in renal transplant recipients - a cross-sectional prospective observational clinical study
- PMID: 33332078
- DOI: 10.18388/abp.2020_5490
The renin-angiotensin-aldosterone system blockade and arterial stiffness in renal transplant recipients - a cross-sectional prospective observational clinical study
Abstract
Introduction: Arterial stiffness parameters can be used as a predictor of cardiovascular events in the general population and renal transplant recipients (RTRs). Additionally, the renin-angiotensin-aldosterone-system (RAAS) blockade mitigates arterial stiffness in the general population. There are no sufficient data concerning the role of the RAAS blockade in reducing arterial stiffness among patients after kidney transplantation. The aim of this study is to assess the influence of the above blockade on arterial stiffness in RTRs.
Methods: 344 stable RTRs were enrolled in the study. 204 (59.3%) of them received RAAS blockers (angiotensin convertase inhibitors - ACEIs or angiotensin receptor blockers - ARBs): group RAAS (+), and 140 (40.7%) were not treated with such agents: group RAAS (-).
Results: In the RAAS (+) group, 55.9% of the patients used ARBs and 44.1% ACEIs. Cardiovascular disease (coronary artery disease and/or peripheral obliterans artery disease) (27.9% vs 14.3%, p<0.05), and heart failure (27.4% vs 24.3%, p<0.05) were significantly more often diagnosed in the RAAS (+) group when compared to the RAAS (-) group. Systolic blood pressure, diastolic blood pressure and all arterial stiffness parameters (baPWV, cfPWV, pulse pressure) did not differ significantly between the RAAS (+) and RAAS (-) groups. The results revealed that cardiovascular disease in patients was associated with a significant increase in both, the PWV and pulse pressure. No difference between the arterial stiffness parameters was observed in patients with a cardiovascular disease, diabetes and heart failure in the RAAS (+) and RAAS (-) groups. Moreover, beta-blockers and diuretics ameliorated the arterial stiffness parameters.
Conclusions: This study showed the indication bias of the RAAS prescription, and no conclusion on the influence of RAAS on arterial stiffness can be drawn. The results indicated diuretics and beta-blockers as agents lowering the arterial stiffness in RTRs.
Similar articles
-
Effects of renin-angiotensin-aldosterone system inhibitors and beta-blockers on markers of arterial stiffness.J Am Soc Hypertens. 2014 Feb;8(2):74-82. doi: 10.1016/j.jash.2013.09.001. Epub 2013 Oct 17. J Am Soc Hypertens. 2014. PMID: 24139833 Clinical Trial.
-
Differential Effects of Combination of Renin-Angiotensin-Aldosterone System Inhibitors on Central Aortic Blood Pressure: A Cross-Sectional Observational Study in Hypertensive Outpatients.Cardiovasc Ther. 2020 Sep 7;2020:4349612. doi: 10.1155/2020/4349612. eCollection 2020. Cardiovasc Ther. 2020. PMID: 32983258 Free PMC article.
-
Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.Trials. 2018 Feb 12;19(1):101. doi: 10.1186/s13063-017-2343-3. Trials. 2018. PMID: 29433578 Free PMC article.
-
Current strategies to achieve further cardiac and renal protection through enhanced renin-angiotensin-aldosterone system inhibition.Rev Recent Clin Trials. 2011 May;6(2):134-46. doi: 10.2174/157488711795177912. Rev Recent Clin Trials. 2011. PMID: 21241234 Review.
-
A Modern History RAAS Inhibition and Beta Blockade for Heart Failure to Underscore the Non-equivalency of ACEIs and ARBs.Cardiovasc Drugs Ther. 2020 Apr;34(2):215-221. doi: 10.1007/s10557-020-06950-w. Cardiovasc Drugs Ther. 2020. PMID: 32219664 Review.
Cited by
-
Update on Treatment of Hypertension After Renal Transplantation.Curr Hypertens Rep. 2021 May 7;23(5):25. doi: 10.1007/s11906-021-01151-8. Curr Hypertens Rep. 2021. PMID: 33961145 Review.
-
Influence of Belatacept- vs. CNI-Based Immunosuppression on Vascular Stiffness and Body Composition.J Clin Med. 2022 Feb 24;11(5):1219. doi: 10.3390/jcm11051219. J Clin Med. 2022. PMID: 35268310 Free PMC article.
-
Empagliflozin Leads to Faster Improvement in Arterial Stiffness Compared to Dapagliflozin: A Double-Blind Clinical.Life (Basel). 2025 May 18;15(5):802. doi: 10.3390/life15050802. Life (Basel). 2025. PMID: 40430228 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
